[European Society of Cardiology guidelines on the management of pulmonary embolism].
In recent years, several studies and new molecules have emerged in the field of pulmonary embolism. Initial patient management requires rapid assessment of clinical condition. In case of shock, a primary reperfusion approach is requi- red (i.e., pharmacological, surgical or percutaneous). In the other cases, the assessment of the risk of early mortality is needed and treatment with anticoagulant should be started. Very low risk patients can be discharged early. High-intermediate risk patients can sometimes benefit from a reperfusion approach. Individual risk stratification can be refined by the assessment of right ventricular function and biomarkers (troponin, B-type natriuretic peptide). The new anticoagulants can be used in this indication. For most patients, the duration of treatment is 3 months. In this article, we summarize the 2014 recommendations of the European Society of Cardiology for the management of pulmonary embolism.